EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices Dec 17, 2021 12:45PM
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination Dec 2, 2021 07:00AM
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference Nov 29, 2021 08:00AM
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa Nov 22, 2021 07:00AM
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership Nov 18, 2021 07:00AM


Nov 16, 2021 08:00AM EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
Oct 19, 2021 01:42PM EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
Oct 6, 2021 06:00AM EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
Sep 27, 2021 08:00AM EQRx Appoints Kathy Giusti to Board of Directors
Sep 17, 2021 07:00AM EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
Sep 13, 2021 08:40PM EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
Sep 7, 2021 08:00AM EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Aug 18, 2021 07:00AM EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
Aug 6, 2021 07:14AM EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III (CMLTU)
Aug 6, 2021 07:00AM EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
Apr 9, 2021 04:20PM CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering
Apr 7, 2021 10:27AM IPO for SPAC CM Life Sciences III (CMLT) Opens at $11
Apr 7, 2021 06:04AM CM Life Sciences III (CMLT) SPAC Prices 48M Shares Upsized Offering at $10
Apr 6, 2021 10:10PM CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering